Medical syringe is seen with Pfizer company logo displayed on a screen in the background in this illustration photo taken in Poland on June 16, 2020. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images) “We’re in a position potentially to be able to offer some hope,” Dr.
Bill Gruber, Pfizer’s senior vice president of clinical development, told The Associated Press. “We’re very encouraged.”AdvertisementAuthorities have stressed it’s unlikely any vaccine will arrive much before the end of the year, and limited initial supplies will be rationed.The shots made by Pfizer and its German partner BioNTech are among 10 possible vaccine candidates in late-stage testing around the world — four of them so far in huge studies in the U.S..